Literature DB >> 10752759

Wegener granulomatosis in children and young adults. A case study of ten patients.

B G Stegmayr1, L Gothefors, B Malmer, D E Müller Wiefel, K Nilsson, B Sundelin.   

Abstract

This retrospective study reports seven children and three young adults (aged 11-30 years) who suffered from Wegener granulomatosis. Nine represent consecutive patients admitted to the Division of Nephrology over a period of 23 years. All patients had respiratory tract symptoms and renal involvement on admission. In several patients infiltrates on chest X-ray developed within 2 weeks of onset of symptoms. All patients survived. The median observation period was 9 years (range 13 months to 23 years). One patient progressed to end-stage renal disease. Nine patients initially received cyclophosphamide and steroids. After a median period of 9 months (range 6-31 months) the cyclophosphamide was replaced by azathioprine. Relapses occurred after a median of 28 months (range 4-120 months) in 80% of patients, in six of the eight patients causing a definite decrease in kidney function. We believe that early diagnosis and initiation of therapy reduce the extent of organ damage. Since relapses are frequent, these patients should be evaluated frequently.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752759     DOI: 10.1007/s004670050043

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

1.  ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome.

Authors:  Ekaterini Siomou; Despoina Tramma; Claire Bowen; David V Milford
Journal:  Pediatr Nephrol       Date:  2012-05-31       Impact factor: 3.714

Review 2.  Granulomatosis with polyangiitis in childhood.

Authors:  Marinka Twilt; Susanne Benseler; David Cabral
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 3.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

4.  Long- term outcome of paediatric patients with ANCA vasculitis.

Authors:  Nishkantha Arulkumaran; Susan Jawad; Stuart W Smith; Lorraine Harper; Paul Brogan; Charles D Pusey; Alan D Salama
Journal:  Pediatr Rheumatol Online J       Date:  2011-06-19       Impact factor: 3.054

5.  Epidemiology and Outcomes of Granulomatosis With Polyangiitis in Pediatric and Working-Age Adult Populations In the United States: Analysis of a Large National Claims Database.

Authors:  Sirada Panupattanapong; Dustin L Stwalley; Andrew J White; Margaret A Olsen; Anthony R French; Mary E Hartman
Journal:  Arthritis Rheumatol       Date:  2018-12       Impact factor: 10.995

Review 6.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: a clinicopathological analysis.

Authors:  Daishi Hirano; Tomoaki Ishikawa; Aya Inaba; Mai Sato; Tomohiro Shinozaki; Kazumoto Iijima; Shuichi Ito
Journal:  Pediatr Nephrol       Date:  2019-05-10       Impact factor: 3.714

8.  Chest CT findings in pediatric Wegener's granulomatosis.

Authors:  Daniel Levine; Jonathan Akikusa; David Manson; Earl Silverman; Rayfel Schneider
Journal:  Pediatr Radiol       Date:  2006-10-28

9.  Pseudotumour orbitae as the initial manifestation in Wegener's granulomatosis in a 7-year-old girl.

Authors:  Kazimierz A Wardyn; Katarzyna Ycińska; Joanna Matuszkiewicz-Rowińska; Małgorzata Chipczyńska
Journal:  Clin Rheumatol       Date:  2003-10-24       Impact factor: 2.980

Review 10.  Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood.

Authors:  Federica Vanoni; Alberto Bettinelli; Franco Keller; Mario G Bianchetti; Giacomo D Simonetti
Journal:  Pediatr Nephrol       Date:  2009-07-30       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.